GAVISCON Tablets Chewable 500/25/100 Milligram

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

ALGINIC ACID MAGNESIUM TRISILICATE ALUMINIUM HYDROXIDE GEL, DRIED SODIUM BICARBONATE

Available from:

Reckitt Benckiser Ireland Ltd

Dosage:

500/25/100 Milligram

Pharmaceutical form:

Tablets Chewable

Authorization date:

1998-04-01

Summary of Product characteristics

License
Part II
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Gaviscon Tablets 
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 500mg Alginic acid, 170 mg sodium bicarbonate, 100 mg Aluminium Hydroxide Gel and 25mg 
Magnesium Trisilicate.
For excipients, see 6.1
3 PHARMACEUTICAL FORM
Chewable tablet.
Circular, flat, off-white to cream, bevel-edged tablets, 0.9 inches in diameter with an odour and flavour of peppermint, 
with ‘Gaviscon’ and sword motif imprinted on both faces.
4 CLINICAL PARTICULARS 
4.1 Therapeutic Indications
Gastric reflux, reflux oesophagitis, heartburn, hiatus hernia, heartburn (including heartburn of pregnancy) and similar 
gastric distress.
4.2 Posology and method of adminstration
Oral.
Adults and children over 12 years: One or two tablets after meals and at bedtime.
Children 6 to 12 years: One tablet after meals and at bedtime.
4.3 Contraindications
None known.
4.4 Special warnings and special precautions for use
Sodium content of a tablet is 47 mg (2.04 mmol). This should be taken into account when a highly restricted salt diet is 
required as in some renal and cardiovascular conditions. Products containing aluminium hydroxide should be used 
with caution in patients with renal dysfunction or hypophosphataemia.
Aluminium hydroxide may cause constipation due to its astringent action; this effect may be balanced by the cathartic 
effect of t